Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2023 | CheckMate-816: what does the data tell us?

Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, Maidstone, UK, discusses the fundamental contribution of the CheckMate-816 trial (NCT02998528) in discerning the preoperative efficacy outcomes of three neoadjuvant chemotherapy cycles. Dr Shah highlights that although no new data was presented at the British Thoracic Oncology Group (BTOG) Annual Conference 2023, a poster reaffirming the treatments pathological complete response (CR) rate and event-free survival was presented at the conference. This interview took place at BTOG 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.